SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SITC SITE Centers Corp.

Closed 04-23 16:00:00 EDT

11.80

-0.09

-0.76%

盘后11.80

+0.000.00%

16:31 EDT

High12.16	Low11.73	Vol567.86K
Open12.16	D1 Closing11.89	Amplitude3.66%
Mkt Cap618.85M	Tradable Cap585.70M	Total Shares52.44M
T/O6.71M	T/O Rate1.14%	Tradable Shares49.64M
P/B1.20	ROE39.06%	EPS9.77
52wk High64.44	52wk Low10.46	P/E1.21
Dividend1.04	Div.Yield0.09	ROA0.87%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SITC","market":"US","secType":"STK","nameCN":"SITE Centers Corp.","latestPrice":11.8,"timestamp":1745438400000,"preClose":11.89,"halted":0,"volume":567861,"hourTrading":{"tag":"盘后","latestPrice":11.8,"preClose":11.8,"latestTime":"16:31 EDT","volume":23920,"amount":282260.75,"timestamp":1745440315307},"delay":0,"floatShares":49635900,"shares":52444903,"eps":9.765244,"marketStatus":"Closed","change":-0.09,"latestTime":"04-23 16:00:00 EDT","open":12.16,"high":12.16,"low":11.725,"amount":6712435.590021,"amplitude":0.036585,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":9.765244,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745481600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":11.89,"aum":0,"dividendRate":0.088136,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":11.89,"preClose":11.89,"latestTime":"08:02 EDT","volume":15,"amount":180.056505,"timestamp":1745409758825},"postHourTrading":{"tag":"盘后","latestPrice":11.8,"preClose":11.8,"latestTime":"16:31 EDT","volume":23920,"amount":282260.75,"timestamp":1745440315307},"volumeRatio":0.876652,"impliedVol":0.3198,"impliedVolPercentile":0.747},"requestUrl":"/m/hq/s/SITC/wiki","defaultTab":"wiki","newsList":[{"id":"2526618388","title":"Should You Retain SITE Centers Stock in Your Portfolio Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526618388","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526618388?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 23:00","pubTimestamp":1744383600,"startTime":"0","endTime":"0","summary":"SITE Centers Corp’s SITC well-located portfolio of retail real estate assets, concentrated mostly in the suburban and high household income regions, positions it well for growth. Its solid tenant roster and focus on the capital-recycling program augur well. However, rising e-commerce adoption and elevated interest rates add to its woes.The company has a solid tenant roster comprising reputed names like TJX Companies, DICK's Sporting Goods, Burlington, Kroger and PetSmart. These tenants hold a relatively strong financial position and have performed well over time. This assures stable rental revenues for the company over the long term.Despite the Federal Reserve announcing rate cuts late in 2024, the interest rate is still high and is a concern for SITE Centers. Elevated rates imply high borrowing costs for the company, affecting its ability to purchase or develop real","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/retain-centers-stock-portfolio-now-150000927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0757428866.USD","BK4104","BK4585","REIT","BK4548","SKT","BK4231","LU2065731478.USD","BK4588","REG","SITE","LU1815336091.USD","SITC","BK4080"],"gpt_icon":0},{"id":"2526923550","title":"CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526923550","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526923550?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 19:30","pubTimestamp":1744284600,"startTime":"0","endTime":"0","summary":"Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation. Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025. Filed IND and CTA submissions for Phase 1 study with proprietary off-the-shelf program in squamous non-small cell lung cancer . Received FDA clearance to proceed with sqNSCLC Phase 1 study; expected tostart in H2 2025. Invoiced 10 million milestone payment following initiation of Phase 1 of the combined Phase 1/2 study of a seasonal influenza/COVID-19 combination vaccine; program fully licensed to GSK. Received positive validity decision for patent EP 3 708 668 B1 in amended form from European Patent Office  in inter partes proceedings against BioNTech SE. Cash and cash equivalents position of 481.7 million as of December 31, 2024; reaffirming expected cash runway into 2028. TBINGEN, GERMANY AND BOSTON, MA / ACCESS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-announces-financial-results-fourth-113000748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTA","BK4535","BK4551","BK4231","CVAC","SITC","BNTX","BK4568","BK4588","BK4585","BK4139","BK4548","BK4080"],"gpt_icon":0},{"id":"2526613364","title":"Xenetic Biosciences, Inc. Releases Virtual Investor \"What This Means\" Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526613364","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526613364?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 21:15","pubTimestamp":1744204500,"startTime":"0","endTime":"0","summary":"- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer  Spring Scientific 2025 Cell Therapy Meeting. FRAMINGHAM, MA / ACCESS Newswire / April 9, 2025 / Xenetic Biosciences, Inc.  , a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing difficult to treat cancers, today announced thatDr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in aVirtual Investor \"What This Means\" segment.As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent poster presentation titled, \"DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma,\" which was presented at theat the Society for Immunotherapy of Cancer  Spring Scientific 2025 Cell Therapy Meeting.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenetic-biosciences-inc-releases-virtual-131500464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XBIOW","SITC","XBIO","BK4139","BK4080","BK4231"],"gpt_icon":0},{"id":"2522558078","title":"Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522558078","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522558078?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"– Initial clinical activity in a PD-1 resistant population, with an ORR almost three times higher than historical PD-1 rechallenge response rates, with data still maturing –。– One durable complete response in a Merkel Cell Carcinoma  patient and two partial responses , including one in a second MCC patient and one in a microsatellite instability-high  Colorectal Cancer  patient, all of whom were previously treated with and progressed on immunotherapy –。– All PD-1 resistant “hot” tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time –。The Phase 1 dose expansion trial is a multi-center, open-label, dose expansion study evaluating solnerstotug as monotherapy and in combination withLibtayo , Regeneron’s PD-1 inhibitor, in both a basket of “hot” tumorsthat typically respond to immunotherapy but have progressed on prior PD-1 therapy and a single “cold” tumor histology  that is typically unresponsive to immunotherapy.At the time of this da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","PD","SD","BK4107","IE00B7SZL793.SGD","BK4585","LU1169590202.USD","BK4080","IE0031619046.USD","CRC","SITC","BK4139","IE00B19Z4B17.USD","IE00B66KJ199.SGD","SNSE","PR","LU2065731478.USD","BK4231","BK4006","BK4161","RCC","L","BK4113","LU1169589451.USD","BK4213","LU0053666078.USD","LU0456854461.SGD","MSS","CRS","CR","LU0266512127.USD","BK4588"],"gpt_icon":0},{"id":"2522374205","title":"Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374205?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:55","pubTimestamp":1743076500,"startTime":"0","endTime":"0","summary":"-      Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.-          EU & UK: Approved for first-line treatment of stage IV non-small cell lung cancer ; stage III NSCLC new indication application submitted to EMA.-     Global Partnerships: Three strategic partnerships across 40+ countries, to accelerate global commercialization.-      Localized Production: Approved for localized manufacturing in China, enhancing cost efficiency.-      Commercial Collaboration: Partnered with Hengrui to expand market access in China.-      Leading Position: Top 2 globally in clinical development for ROR1-targeted ADCs.-      Preclinical Differentiation: Superior tumor suppression vs. benchmarked competitors; potential first-in-class/best-in-class IO backbone therapy.-      More than 9 Differentiated Candidates: Focus on first-in-class/best-in-class assets, including multispecific antibodies and ADCs, with global rights and broad therapeutic potential.SUZHOU, Ch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4570","LU2294711713.HKD","CDE","BK1574","BK4232","LU1642822529.SGD","BK4588","LU2506951792.HKD","BK4109","LU1815336760.USD","R","PRGS","CEE","BK4182","LU2065732104.USD","ORR","LU0444971666.USD","LU2357125470.USD","BK4195","BK4213","SOC","BK4017","BK4080","BK4585","LU0476273544.USD","LU0823414551.USD","BK4022","ADC","LU2249611893.SGD","SITC","BK1161","BK4124","LU0345780521.USD","BK4541","PFS","LU0444973449.USD","BK4231","LU2463526074.USD","02616","OS","LU0823414478.USD","BK4097","ASH","CPS","HL","BE","LU0957808578.USD","BK4210"],"gpt_icon":0},{"id":"2522379271","title":"Press Release: TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379271","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379271?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:30","pubTimestamp":1743075000,"startTime":"0","endTime":"0","summary":"-- Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024,Representing Growth of 44% And 59%, Respectively, Versus the Prior Year. -- Gross Margin of 85% and 86% for Q4 and Full-Year 2024. 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash. \"We were also pleased to strengthen our Board of Directors with the additions of William Valle and Dr. Gary Gordon. Additionally, we want to sincerely thank Sean Murphy for his leadership in guiding the Company through the process of going public, a milestone that would not have been possible without his dedication and expertise. We are thrilled to welcome him back to the Board of Directors and look forward to his continued contributions to our success,\" concluded Ms. Szela.These new products are eligible for the same HCPCS reimbursement codes as existing TriNav products, which should enable seamless integration into current billing structures. The Company believes these expanded features","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2346227817.USD","LU1894683264.USD","BK4232","BK4099","TLSI","BK4139","BK4231","LU2637428348.USD","LU2500361329.USD","R","BK4588","BK4585","CMS","BK4208","TM","03160","BK4555","SITC","BK4604","BK4022","LU1894683348.USD","BK4080"],"gpt_icon":0},{"id":"2522193123","title":"Press Release: Innate Pharma Reports Full Year 2024 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522193123","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522193123?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 14:00","pubTimestamp":1743055200,"startTime":"0","endTime":"0","summary":"-- FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or. -- New data, including lacutamab improved health-related quality of. life data from TELLOMAK Phase 2 study in patients with cutaneous T. -- IPH6501, Innate's proprietary ANKET drug candidate, is being evaluated. -- Innate Pharma and the Institute for Follicular Lymphoma Innovation. Innate Pharma SA   today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release.\"Our strategy is clear: drive innovation through our ANKET NK-cell engager platform and accelerate our ADC programs. We are making strong clinical progress, with our lead proprietary ANKET , IPH6501 advancing in B-cell non-Hodgkin's lymphoma and commencing the Phase 1 study for the Nectin-4 ADC IPH4502 in solid tumors. The FDA's Breakthrough Therapy Designation for lacutamab highlights its potential to transform treatment for Sézary syndrome. With these ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IPHA","BK4231","BK4022","BK4094","BK4588","R","FL","SITC","BK4080","BK4139","BK4232","IPHYF"],"gpt_icon":0},{"id":"2522805834","title":"SITE Centers Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805834","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805834?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 21:00","pubTimestamp":1742994000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SITC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 09:00 ET (13:00 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU0070302665.USD","LU1035773651.USD","LU0162691827.USD","LU0683600562.USD","LU2361044949.HKD","SITC","LU0310800379.SGD","LU0175139822.USD","LU0149725797.USD","LU0477156953.USD","LU1074936037.SGD","LU0708994859.HKD","LU0267386448.USD","LU1069347547.HKD","LU1814569148.SGD","SITE","LU1668664300.SGD","LU1267930573.SGD","LU2461242641.AUD","LU0211327993.USD","LU0072461881.USD","LU0029864427.USD","LU0130102774.USD","LU0154236417.USD","BK4585","IE00B7SZLL34.SGD","LU0128525689.USD","IE0002270589.USD","LU0052756011.USD","LU0314106906.USD","LU0640476718.USD","LU0251131958.USD","LU1267930227.SGD","LU2236285917.USD","LU2361045086.USD","BK4104","LU0208291251.USD","LU0048573561.USD","LU1267930490.SGD","LU1363072403.SGD","LU0971096721.USD","BK4504","LU2065731478.USD","LU0106831901.USD","BK4501","BK4231","LU1506573853.SGD","BK4588"],"gpt_icon":0},{"id":"2520743010","title":"Adaptimmune Provides Q4 and Full Year 2024 Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520743010","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520743010?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"TECELRA launch momentum accelerating– 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved. Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026. Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs. At the end of 2024, Adaptimmune had Total Liquidity1 of $152 million. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: \"2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise. The launch is going very well and each step in delivering this important medicine: activating our treatment network; identifying biomarker eligible patients; exceptional manufacturing quality and turn-around times, strengthens our sarcoma platform capabilities for both Tecelra and for lete-cel. These results give us confidence in our strategy to build value from our sarcoma franchise a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adaptimmune-provides-q4-full-2024-110000539.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmune-provides-q4-full-2024-110000539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4231","SITC","BK4139","ADAP"],"gpt_icon":0},{"id":"2519389886","title":"Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519389886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519389886?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 06:07","pubTimestamp":1741903620,"startTime":"0","endTime":"0","summary":"○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042670/0/en/Cellectis-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2024-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","CAR","RCC","BK4201","SITC","BK4231","BK4230","CLLS","BK4080","BK4022","ODD","BK4183","BK4139"],"gpt_icon":0},{"id":"2519586929","title":"Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2519586929","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519586929?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 04:15","pubTimestamp":1741896900,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights. -- Recently announced positive data from pivotal randomized,placebo-controlled phase 3 clinical trial of CAN-2409 in. prostate cancer underway, with submission expected in Q4 2026. Dr. Tak continued, \"We enter 2025 well-resourced with a clear direction and mandate. Our primary focus for the year is working toward readiness to submit CAN-2409's BLA for prostate cancer, a key opportunity to address a very significant unmet need and opportunity for value creation. In addition, we continue to explore the efficacy of CAN-2409 in other indications, as evidenced by our recently disclosed positive final overall survival data for CAN-2409 in a randomized controlled phase 2a trial in borderline resectable pancreatic cancer. This result has triggered enabling work, which will include scientific advisory boards and engagement with the FDA, to get ready for a larger, late-stage, randomiz","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4595","BK4526","SITC","CADL","DFS","LU1861220207.SGD","BK4139","LU2360107671.USD","LENZ","BK4231","LU1861217088.USD","LU1668664300.SGD","BK4080","BK4585","BK4555","LU1791807156.HKD","BK4600","BK4170","BK4099","BK4604","TM","LU0106831901.USD","BK4166","BK4539","BK4588"],"gpt_icon":1},{"id":"2519396918","title":"Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses","url":"https://stock-news.laohu8.com/highlight/detail?id=2519396918","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519396918?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:30","pubTimestamp":1741869000,"startTime":"0","endTime":"0","summary":"Data presented at the Society for Immunotherapy of Cancer  Spring Scientific 2025 Cell Therapy Meeting. Findings demonstrate that by degrading neutrophil extracellular traps , DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more effective cancer treatment strategies. FRAMINGHAM, MA / ACCESS Newswire / March 13, 2025 / Xenetic Biosciences, Inc.  , a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I  with chimeric antigen receptor  T cells in a syngeneic B16 melanoma murine model of lung metastasis.The poster titled, \"DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma,\" was presented on behalf of the Company by Alexey Stepanov, PhD, Institute","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenetic-biosciences-inc-presents-positive-123000628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4526","IE00B12V2V27.USD","LU1023057109.AUD","IE00BYQNZ168.SGD","LU2039709279.SGD","BK4552","BK4080","BK4139","BK4548","LU0359201612.USD","SG9999011746.SGD","01698","SITC","LU0359202008.SGD","IE00BYTNYN87.SGD","BK4535","BK4571","CAR","BK4509","XBIOW","BK4563","BK4531","XBIO","TME","BK4022","BK4565","BK4230","BK4108"],"gpt_icon":0},{"id":"2519386248","title":"Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386248","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386248?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:30","pubTimestamp":1741865400,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update. -- Company Achieves Key Clinical Milestone with more than 20 Patients. Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20. -- Pharmacodynamic immune activation biomarker and pharmacokinetics profiles. in initial data sets appear to meet or exceed initial expectations. -- Early signs of potential benefit emerge with some patients demonstrating. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, \"We continue to make significant progress in our Phase 1 trial of Decoy20, and enrolling more than 20 patients in the weekly dosing cohort marks an important milestone. We are particularly encouraged by the emerging clinical data, with some patients in this cohort demonstrating stable disease - an early sign that Decoy20's immune-modulating approach may be having a meaningful impact. With a favorable safety profile observed so far, we are focused on efficiently a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4606","BK4139","SITC","NLR","INDP","BK4231","BK4080"],"gpt_icon":0},{"id":"2517132651","title":"NextCure Provides Business Update and Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517132651","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517132651?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:05","pubTimestamp":1741295100,"startTime":"0","endTime":"0","summary":"Cash of approximately $68.6 million expected to fund operations into the second half of 2026. BELTSVILLE, Md., March 06, 2025  -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results.“In 2024 we reprioritized our resources to advance our antibody-drug conjugate  program and recently completed cohort 1 of the Phase 1 study evaluating LNCB74 as a potential therapeutic for treating multiple cancers. We look forward to additional progress in 2025, including initiating backfill cohorts in the second half of the year,” said Michael Richman, NextCure’s president and CEO.Presented preclinical data from LNCB74  at the Society of Immunotherapy of Cancer  annual meeting in November 2024 to highlight its potential as a therapeutic for treating multiple solid tumor indications.Preclinical data for NC181 , a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nextcure-provides-business-reports-full-210500630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4126","NXTC","SITC","BK4080","OI","BK4231","BK4139"],"gpt_icon":0},{"id":"2517911392","title":"Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911392","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911392?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":"Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis  patient cohort in 1H25. Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25. Initiation of ADI-001 Phase 1 clinical trial patient enrollment in systemic lupus erythematosus , systemic sclerosis , idiopathic inflammatory myopathy  and stiff person syndrome  expected in 2Q25; anti-neutrophil cytoplasmic autoantibody  associated vasculitis  patient enrollment expected to be initiated in 2H25. Continuing to advance phase 1 trial of ADI-001 in autoimmune diseases. In November 2024, Adicet announced the dosing of the first patient in the Phase 1 trial evaluating ADI-001 in LN. Enrollment for SLE, SSc, IIM, and SPS patients is expected to commence in the second quarter of 2025, with the initiation of AAV patient enrollment anti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-reports-fourth-quarter-210100654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065732104.USD","ACR","ACET","BK4022","BK4230","IIM","SLE","BK4110","BK4097","BK4139","CAR","PRGS","BK4231","BK4080","SITC","BK4077"],"gpt_icon":0},{"id":"2517666118","title":"Press Release: Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517666118","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517666118?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:00","pubTimestamp":1741294800,"startTime":"0","endTime":"0","summary":"-- DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025,-- Strategic partnership with Orano Med on Radio-DARPins now expanded to ten. -- MP0533 Phase 1/2a clinical data show improved response rate and depth in. ongoing cohort, additional dosing optimization planned; data expected. and short-term deposits at end of 2024, expected to support operations. \"Molecular Partners has made significant progress through 2024, setting us up for a number of key value inflection points. The potential of our Radio-DARPins is now well recognized in the field. In addition, we are advancing our next-generation immuno-oncology programs, including multispecific and Switch-DARPin T cell engagers\", said Patrick Amstutz, Ph.D., Chief Executive Officer of Molecular Partners.The Investigational New Drug  application for MP0712, a  Pb Radio-DARPin therapy  candidate targeting the tumor-associated protein delta-like ligand 3  and co-developed with Orano Med, is in preparation. Dialogue with th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","TRP","IE00BMG7P819.SGD","LU2463526074.USD","BK4109","TAT","IE00BMG7P926.USD","BK4080","BK4513","SWCH","BK4116","SITC","BK4566","IE00BMG7P587.USD","BK4539","ASH","LU1093756325.SGD","IE00BMG7P694.USD","BK4139","LU1093756168.USD","MOLN","BK4231"],"gpt_icon":0},{"id":"2517921680","title":"Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921680","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921680?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:05","pubTimestamp":1741208700,"startTime":"0","endTime":"0","summary":"First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor- (FR) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelinAc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037747/0/en/Zymeworks-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4585","BTC","BK4181","PK","SITC","BK4218","BK4581","BK4590","BK4561","ET","BK4144","BK4080","BK4231","BK4588"],"gpt_icon":0},{"id":"2517792973","title":"Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517792973","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517792973?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:01","pubTimestamp":1741208460,"startTime":"0","endTime":"0","summary":"Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE. Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T-cell Dose Expansion in Additional B Cell-mediated Autoimmune Diseases. First FT819 Off-the-Shelf CAR T-cell Patient Treated without Conditioning Chemotherapy as Add-on to Maintenance Therapy in SLE. Phase 1 Dose Expansion Initiated for SLE using Flu-free Conditioning Regimen. Based on clinical data from the first three patients treated with FT819 in its ongoing multi-center, Phase 1 clinical trial for moderate-to-severe systemic lupus erythematosus  , the Company has initiated dose expansion in up to 10 patients at 360 million cells. The dose expansion stage is designed to evaluate the safety and efficacy of a fludarabine -free conditioning regimen, consisting of either bendamustine alone or cyclophosphamide alone, followed by a single dose of FT819. The Company is also a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-reports-fourth-quarter-210100391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASH","FATE","SLE","IE00B66KJ199.SGD","BK4230","BK4022","CAR","BK4080","SITC","BK4139","TRAC","IE00B19Z4B17.USD","IIM","BK4112","IE00B7SZL793.SGD","BK4077","CRS","LU2065731478.USD","LU2463526074.USD","BK4006","BK4109","BK4231","IE0031619046.USD"],"gpt_icon":0},{"id":"2517991147","title":"CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14","url":"https://stock-news.laohu8.com/highlight/detail?id=2517991147","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517991147?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:15","pubTimestamp":1741180500,"startTime":"0","endTime":"0","summary":"New poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March  05, 2025  (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037386/0/en/CERo-Therapeutics-Holdings-Inc-to-Present-Data-at-the-Society-for-Immunotherapy-of-Cancer-Spring-Scientific-March-12-14.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","SITC","BK4231"],"gpt_icon":0},{"id":"2516877986","title":"Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2516877986","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516877986?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035440/0/en/Aura-Biosciences-Announces-Additional-Data-from-Ongoing-Phase-1-Trial-in-Non-Muscle-Invasive-Bladder-Cancer-to-be-Presented-as-a-Late-Breaking-Abstract-at-the-40th-Annual-European-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AURA","BK4588","SITC","BK4231","VDC","BK4585","BK4080"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sitecenters.com","stockEarnings":[{"period":"1week","weight":0.0241},{"period":"1month","weight":-0.0718},{"period":"3month","weight":-0.2094},{"period":"6month","weight":-0.3075},{"period":"1year","weight":-0.7838},{"period":"ytd","weight":-0.2224}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.","yearOnYearQuotes":[{"month":1,"riseRate":0.46875,"avgChangeRate":0.000763},{"month":2,"riseRate":0.580645,"avgChangeRate":0.006952},{"month":3,"riseRate":0.636364,"avgChangeRate":-0.002734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.028942},{"month":5,"riseRate":0.4375,"avgChangeRate":0.000981},{"month":6,"riseRate":0.75,"avgChangeRate":0.022019},{"month":7,"riseRate":0.65625,"avgChangeRate":0.015994},{"month":8,"riseRate":0.46875,"avgChangeRate":0.00249},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.015322},{"month":10,"riseRate":0.4375,"avgChangeRate":-0.04178},{"month":11,"riseRate":0.46875,"avgChangeRate":0.001368},{"month":12,"riseRate":0.625,"avgChangeRate":0.0148}],"exchange":"NYSE","name":"SITE Centers Corp.","nameEN":"SITE Centers Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SITE Centers Corp.(SITC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SITE Centers Corp.,SITC,SITE Centers Corp.股票,SITE Centers Corp.股票老虎,SITE Centers Corp.股票老虎国际,SITE Centers Corp.行情,SITE Centers Corp.股票行情,SITE Centers Corp.股价,SITE Centers Corp.股市,SITE Centers Corp.股票价格,SITE Centers Corp.股票交易,SITE Centers Corp.股票购买,SITE Centers Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SITE Centers Corp.(SITC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction